Comparative Pharmacology
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus RAU SED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus RAU SED.
METHYCLOTHIAZIDE AND DESERPIDINE vs RAU-SED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
None Documented
None Documented
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Category C
Category C
Thiazide Diuretic and Antihypertensive
Antihypertensive